Oncology Views & Analysis

Views & Analysis

Oncology

Resilience, empathy, and gratitude. A personal battle with b...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Nataliya Andreychuk, CEO of Viseven, about her personal battle with breast cancer.

Oncology

ADCs shine at ESMO ’23, as pharma makes case for early immun...

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac

Oncology

Where old pathways to innovative cancer care fall short, a n...

Ignoring half the people in the world cannot be good for business.

Oncology

CAR-TCR 2023 – Jonathan Wofford

In order for cell therapies to scale effectively, the industry is clamouring for standardisation around things like manufacturing and treatment administration.

Oncology

The ‘elegant science’ in achieving the promise of ADCs

In this week’s episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Raquel Izumi, chief operating officer and co-founder of Vincerx Pharma, who is on a mission to impr

Oncology

CAR-TCR 2023 – Mindy Miller

As more cell therapies are approved and the category emerges, there’s also an increased need for the technology that enables cell therapy development.

Resilience, empathy, and gratitude. A personal battle with b...

ADCs shine at ESMO ’23, as pharma makes case for early immun...

Where old pathways to innovative cancer care fall short, a n...

CAR-TCR 2023 – Jonathan Wofford

The ‘elegant science’ in achieving the promise of ADCs

CAR-TCR 2023 – Mindy Miller

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Views & Analysis

Editor's Picks